By Tony Fong

NEW YORK (GenomeWeb News) – Diagnostic companies developing biomarker-based tests usually work with patient samples from subjects who already have a disease for comparison with samples taken from healthy subjects.

But leveraging a biobank that it has licensed from University College London, UK firm Abcodia is betting that samples that allow researchers to track changes in patients going back years to before the onset of disease and through the progression of disease can provide new methods of disease detection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.